

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085196 A2

(51) International Patent Classification⁷: **C07D 209/48**

(74) Agent: **HUHN, Michael**; Isenbruck, Bösl, Hörschler, Wichmann, Huhn, Patentanwälte, Theodor-Heuss-Anlage 12, 68165 Mannheim (DE).

(21) International Application Number:
PCT/EP2005/002437

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 8 March 2005 (08.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04005498.3 8 March 2004 (08.03.2004) EP
04014619.3 22 June 2004 (22.06.2004) EP

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **DKFZ** [DE/DE]; Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts, Im Neuenheimer Feld 280, 69120 Heidelberg (DE). **INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS PAS** [PL/PL]; Pawinskiego 5a, 02-106 Warszawa (PL).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **GARCIA BOY, Regine** [DE/DE]; Mönchhofstrasse 54, 69120 Heidelberg (DE). **LYKO, Frank** [DE/DE]; Albert-Mays-Strasse 3, 69115 Heidelberg (DE). **SIEDLECKI, Pawel** [PL/PL]; Mokotowska 24/4, PL-00-560 Warschau (PL).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF DNA METHYLATION IN TUMOR CELLS



(57) Abstract: The present invention relates to compounds according to the general formula (I) wherein the dotted lines denote a single bond which is optionally present, with 2 dotted lines denoting a double bond; wherein, in case no double bond is present and a free valence exists, this valence is occupied by H; and wherein the symbols have the meanings defined in the text, or a pharmaceutically acceptable salt thereof, and which lend themselves for the manufacture of drugs useful in the inhibition of DNA methylation, the inhibition of DNA methyltransferases, and may therefore be useful for the manufacture of pharmaceuticals for the treatment of developmental disorders such as Prader-Willi-Syndrome, Angelman Syndrome (Happy Puppet Syndrome), Beckwith-Wiedemann-Syndrome, and proliferative diseases, such as coronary restenosis and neoplastic diseases, particularly colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, prostate carcinoma, melanoma, non-Hodgkin lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. These compounds may also be used for other applications including the induction of cellular differentiation, diagnosis, and the use in screening assays.

WO 2005/085196 A2